Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IOngoingJul 24, 2024Potassium Chloride Extended-Release CapsulesFailed Dissolution SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0604-2024Class IICompletedJul 24, 2024Cardura XLFailed Impurities/Degradation SpecificationsViatris Inc · D-0603-2024Class IICompletedJul 24, 2024Cardura XLFailed Impurities/Degradation SpecificationsViatris Inc · D-0602-2024Class IIOngoingJul 24, 2024Fludrocortisone Acetate TabletsFailed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.Teva Pharmaceuticals USA, Inc · D-0601-2024Class IITerminatedJul 24, 2024Cyanocobalamin InjectionPresence of particulate matter: glassZydus Pharmaceuticals (USA) Inc · D-0600-2024Class IIOngoingJul 24, 2024Oatmeal Daily Moisturizing Body LotionMicrobial Contamination of Non-Sterile Products: confirmed presence of mold contaminationBrands International Corporation · D-0598-2024Class IITerminatedJul 24, 2024Nitrofurantoin CapsulesFailed Dissolution SpecificationsSun Pharmaceutical Industries Inc · D-0597-2024Class IIIOngoingJul 17, 2024Diflorasone Diacetate OintmentFailed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.Rising Pharma Holding, Inc. · D-0599-2024Class IIICompletedJul 17, 2024Micafungin for injectionCross contamination with other productsZydus Pharmaceuticals (USA) Inc · D-0596-2024Class IIICompletedJul 17, 2024Micafungin for injectionCross contamination with other productsZydus Pharmaceuticals (USA) Inc · D-0595-2024Class IIOngoingJul 17, 2024Lidocaine HCL InjectionSubpotent Drug: reduced efficacy for epinephrineTailstorm Health Inc · D-0594-2024Class IIIOngoingJul 17, 2024Verapamil Hydrochloride InjectionCross contamination with other products.Zydus Pharmaceuticals (USA) Inc · D-0593-2024Class IIIOngoingJul 17, 2024Verapamil Hydrochloride InjectionCross contamination with other products.Zydus Pharmaceuticals (USA) Inc · D-0592-2024Class IITerminatedJul 17, 2024Blemfree All Day LotionCGMP Deviations: Manufactured without following Current Good Manufacturing Practises.Equibal Inc · D-0591-2024Class IIOngoingJul 17, 2024buPROPion Hydrochloride Extended-release Tablets USPFailed Dissolution Specifications; the product is dissolving faster than the specified limits.Amerisource Health Services LLC · D-0590-2024Class IIOngoingJul 17, 2024suntegrityCGMP DeviationsSynchronicity Spa Inc, Dba Sunte · D-0589-2024Class IOngoingJul 17, 2024suntegrityMicrobial Contamination of Non-Sterile Products: Presence of Aspergillus Sydowii (Mold)Synchronicity Spa Inc, Dba Sunte · D-0588-2024Class IIOngoingJul 17, 2024Dianeal Low CalciumLack of Assurance of Sterility: Potential presence of leaks originating from the Connector Assembly component.Baxter Healthcare Corporation · D-0587-2024Class IOngoingJul 10, 2024To the Moon CapsulesMarketed Without an Approved NDA/ANDA: Products contain undeclared sildenafil.Integrity Products · D-0586-2024Class IOngoingJul 10, 2024RAM IT, Horny Goat WeedMarketed Without an Approved NDA/ANDA: Products contain undeclared sildenafil.Integrity Products · D-0585-2024Class IITerminatedJul 10, 2024Venlafaxine HydrochlorideFailed dissolution specifications: out of specification result obtained during routine stability testing for high dissolution.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0584-2024Class IITerminatedJul 10, 2024Allopurinol TabletsPresence of foreign substance.Dr. Reddy's Laboratories, Inc. · D-0583-2024Class IIOngoingJul 10, 2024Decitabine for Injection 50mg per vialCGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.Sun Pharmaceutical Industries Inc · D-0582-2024Class IIIOngoingJul 10, 2024Eszopiclone TabletsFailed Impurities/Degradation Specifications: Related SubstancesDr. Reddy's Laboratories, Inc. · D-0581-2024Class IIITerminatedJul 10, 2024Dodex InjectableSubpotent drug: out of specification resultsAccord Healthcare, Inc. · D-0580-2024Class IITerminatedJul 10, 2024Methylphenidate HydrochlorideFailed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications.Trigen Laboratories · D-0579-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0578-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0577-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0576-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0575-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0574-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0573-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0572-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0571-2024Class IICompletedJul 10, 2024BudesonideCGMP Deviations and Presence of Particulate Matter: GlassMedisca Inc. · D-0570-2024Class IIIOngoingJul 3, 2024SinuFrin DecongestantSub-potent DrugNeilmed Pharmaceuticals Inc · D-0569-2024Class IITerminatedJul 3, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.Golden State Medical Supply Inc. · D-0568-2024Class IIOngoingJul 3, 2024ZilrettaFailed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿CPacira Pharmaceuticals Inc · D-0567-2024Class IIOngoingJul 3, 2024Extra Strength Acetaminophen 500 MG TabletsDiscoloration: Brownish tabletsContract Pharmacal Corporation · D-0566-2024Class IIOngoingJul 3, 2024Labetalol Hydrochloride InjectionLack of Assurance of Sterility-The potential for incomplete crimp seals.Pfizer Inc. · D-0565-2024

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.